Abstract | BACKGROUND AND OBJECTIVE: METHODS: A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. A meta-analysis of all RCTs meeting these criteria was then performed. RESULTS: Three RCTs of patients with Alzheimer's disease (n = 178, mean age 78 years), stroke (n = 99, mean age 66 years) and Parkinson's disease (n = 110, mean age 72 years) met the criteria for meta-analysis. These RCTs did not include placebo controls but did have non-treatment controls. According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. No severe adverse events were reported with menatetrenone treatment. CONCLUSION: The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. Further larger placebo-controlled trials are needed to confirm the results of the present study.
|
Authors | Jun Iwamoto, Hideo Matsumoto, Tsuyoshi Takeda |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 29
Issue 7
Pg. 471-479
( 2009)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 19499964
(Publication Type: Journal Article, Meta-Analysis, Review, Retracted Publication)
|
Chemical References |
- Bone Density Conservation Agents
- Vitamin K 2
- menatetrenone
|
Topics |
- Aged
- Bone Density Conservation Agents
(therapeutic use)
- Brain Diseases
(complications)
- Female
- Fractures, Bone
(complications, drug therapy)
- Hip Fractures
(complications, drug therapy)
- Humans
- Male
- Randomized Controlled Trials as Topic
- Vitamin K 2
(analogs & derivatives, therapeutic use)
|